RU2266747C1 - Probiotic composition for animals and poultry - Google Patents

Abstract

FIELD: biotechnology.

SUBSTANCE: the present innovation deals with biopreparations for agriculture indicated for prophylaxis and treatment of poultry diseases. The probiotic composition suggested contains the strain Rhuminococcus albus Kr, the strain Bacillus subtilis VKPM V-8130 and Lactobacillus acidophilus Scav. VKPM V-4625 at equal quantities. The innovation combines antimicrobial body protection along stimulating impact upon it at simultaneous increase of fodder conversion at high content of fiber, broadened assortment of curative-prophylactic preparations of natural origin.

EFFECT: higher efficiency of prophylaxis and therapy.

4 ex, 3 tbl

Description

The invention relates to applied biotechnology, namely to biological products for agriculture, intended for the prevention and treatment of diseases for animals and birds.

It is known to use various veterinary drugs to combat infectious diseases, such as antibiotics of various groups, furatsilin, phthazine, biofusol, etc. (Veterinary preparations // under the editorship of A.D. Tretyakov, M .: Agropromizdat, 1988, pp. 3-31, 75-94).

However, the disadvantage of most drugs, in particular antibiotics, is the presence of side effects, in particular a violation of the intestinal microflora of animals and birds, which leads to gastrointestinal upsets.

Known widely used biovit preparation containing a mixture of an antimicrobial agent - chlortetracycline and a normalizing component - vitamin B ₁₂ . Biovit is administered orally with water or milk 1 time per day for 8-23 days (Veterinary drugs // edited by A.D. Tretyakov, Moscow: Agropromizdat, 1988. P.8-9).

The disadvantage of biovit is the duration of administration and the possibility of signs of dysbiosis in animals and birds. In addition, the antibiotic chlortetracycline is able to accumulate in the tissues and thereby reduce the quality of livestock products. In addition, with the help of the proposed drug does not occur the formation of normal microflora of the gastrointestinal tract, since it does not contain live microorganisms.

Known dry probiotic for ruminants rumenolact containing a dry bacterial concentrate of the Streptococcus species, characterized in that it further comprises dry bacterial concentrates Lactobacillus casei MB VKPM B-4486 and Lactobacillus acidophilus var. coccoideus M 86 VKPM B-4992, and from the bacterial species Streptococcus contains a dry bacterial concentrate Streptococcus lactis K12 B-4989 in the following ratio, wt. hours:

Lactobacillus casei MB VKPM B-4486 0.8-1.2 Lactobacillus acidophilus var. coccoideus M 86 VKPM B-4992 0.8-1.2 Streptococcus lactis K12 B-4989 0.8-1.2

(RF patent No. 2063755, CL 6 A 61 K 35/06. Bull. No. 20 from 07.20.96 g).

However, in the prototype, microorganisms contain only a group of lactic acid bacteria that can only normalize the microflora of the gastrointestinal tract. At the same time, the microorganisms included in this drug are not able to secrete proteolytic enzymes to destroy dead cells, are not able to synthesize immunomodulators, as well as a number of biologically active substances. In addition, the absence of pronounced cellulolytic activity in this group of microorganisms requires the introduction of enzyme preparations into poultry feed that can destroy fiber from soybean and sunflower meal and meal.

The closest probiotic composition for veterinary medicine is a composition containing pure cultures of Lactobacillus plantarum 8 PA 3, Rhuminococcus albus 1-33, Bacillus subtilis 534, taken in equal amounts (RF Patent No. 2084233, CL 6 A 61 K 35/66. Bull. No. 20 dated 07/20/97 - prototype).

However, in the known method it is used as one of the components of the probiotic preparation Lactobacillus plantarum, which due to its properties is widely used in silage of the green mass of plants, but is used little to normalize the functioning of the gastrointestinal tract. In addition, this method does not indicate the source from which the microorganisms used in the preparation are isolated, which cannot ensure the high efficiency of the proposed drug. It should be noted that such a drug cannot have a complex effect: probiotic, antimicrobial, immunomodulating and have cellulolytic activity.

Known formulations do not allow the effective prevention and treatment of dysbiosis, providing a combination of antimicrobial protection with a stimulating effect on the body and at the same time increasing the conversion of feed with a high fiber content in it to increase the productivity of animals and birds.

The technical solution to the problem is to create a composition that effectively combines the antimicrobial protection of the body with a stimulating effect on it, while increasing the conversion of feed with a high fiber content to increase the productivity of animals and birds, and expanding the range of therapeutic and prophylactic drugs of natural origin.

This object is achieved in that the probiotic composition for animals and birds containing bacteria Rhuminococcus albus, Bacillus subtilis and the genus Lactobacillus taken in equal amounts, moreover, Rhuminococcus albus contains a strain of Rhuminococcus albus Kr., And Bacillus subtilis contains a strain of Bacillus subtilis VKPM B-8130, and from bacteria of the genus Lactobacillus, contains Lactobacillus acidophilus Scav. VKPM B-4625.

The claimed probiotic composition for animals and birds differs from the prototype in the qualitative composition of the microorganisms included in it (other strains are used) and a different type of bacteria of the genus Lactobacillus.

These differences allow us to conclude that the claimed technical solutions meet the criterion of "novelty."

The features that distinguish the claimed technical solution from the prototype are aimed at achieving the task and have not been identified in the study of this and related fields of science and technology and, therefore, meet the criterion of "inventive step".

The production name of the probiotic composition is the word formed from the words bacillus and substrate assimilating cellulose microorganisms included in the composition of the composition - “Bacell”.

The inventive probiotic composition "Bacell" is a complex therapeutic drug that includes microorganisms that can develop in the gastrointestinal tract of animals and birds and can have a positive effect on the host. Each of the components of the drug is capable of performing certain physiological functions in the body of an animal and bird. So, lactic acid bacteria of the species Lactobacillus acidophilus Scav. VKPM B-4625, being normal inhabitants of the gastrointestinal tract of animals and birds (as opposed to the type stated in the prototype), entering the host organism, they release biogenic organic acids (primarily lactic acid), inhibiting the growth and development of pathogenic microflora. Bacteria Bacillus subtilis VKPM B-8130 produces substances with antimicrobial, immunostimulating effect. Rhuminococcus albus Kr, having a high cellulolytic activity, promotes the digestion of fiber, which is part of the feed.

The factors that determine the preparation of a given property include the percentage ratio between the components that make up its composition.

The following bacteria Lactobacillus acidophilus Scav are used as components to obtain the Bacell probiotic composition. VKPM B-4625, Bacillus subtilis VKPM B-8130, Rhuminococcus albus Kr, taken in equal proportions.

If introduced into the drug Lactobacillus acidophilus Scav. VKPM B-4625 is less than 0.8, then there will be no probiotic activity of the drug, because the number of bacteria will not be enough. If you add more than 1.2, then the antimicrobial effect does not increase, and therefore there is no need to introduce more bacteria. In order for the effectiveness of the drug to be optimal, the number of lactic acid bacteria of the species Lactobacillus acidophilus Scav. VKPM B-4625 should be 1.0. If you add less than 0.8 to the Bacillus subtilis VKPM B-8130 preparation, then the antimicrobial and immunostimulating activities of the drug will be low, since the number of bacteria will be insufficient. If you add more than 1.2, then an increase in the required effect will not be observed. In order for the effectiveness of the drug to be optimal, the number of bacilli of the species Bacillus subtilis VKPM B-8130 should be 1.0. If Rhuminococcus albus Kr is added to the preparation, less than 0.8, then the cellulolytic activity of the drug will not be recorded, because the number of bacteria will not be enough for an effective process of destruction of fiber. If you add more than 1, 2, then the rate of destruction of fiber will not increase, since the substrate for their development will not be enough. In order for the cellulolytic effectiveness of the drug to be optimal, the number of bacteria of the species Rhuminococcus albus Kr should be 1.0.

The industrial effectiveness of the proposed probiotic composition "Bacell" is illustrated by examples.

Example 1. The test of the proposed composition was carried out at the poultry factory "Kuban", Ust-Labinsky district of the Krasnodar Territory in the form of an additive for growing broilers of cross-country "SK-Rus". The experimental design is presented in table 1.

Table 1 Broiler Chicken Experience Scheme Group Number of goals Characteristics of feeding (fiber level in the diet) Control 120 The main feed mixture is compiled according to VNITIP standards - fiber content of 3.9-4.2% for growing periods I experienced 120 OK + 0.2% of the proposed composition: fiber level 3.9-4.2-4.8 II experienced 120 OK + 0.2% of the proposed composition: fiber level 3.9-4.5-5.0 III experienced 120 OK + 0.2% of the proposed composition: fiber level 3.9-5.0-5.5 IV experienced 120 OK + 0.2% of the proposed composition; fiber level 3.9-5.0-6.0

The main results of evaluating the effectiveness of the proposed drug in the diets of broiler chickens with different levels of fiber are presented in table 2.

table 2 The main results of evaluating the effectiveness of the proposed drug in the diets of broiler chickens with different levels of fiber Group The level of fiber in the diet by periods,% Live weight of the bird in 49 days, kg The cost of feed per 1 head, kg Feed costs per 1 kg of live weight gain The cost of feed per 1 head, rubles The cost of feed per 1 kg of live weight, rubles Control 3.9-4.2-4.8 1,740 4,178 2.45 7.27 4.26 I experienced 3.9-4.2-4.8 1,850 4,180 2,30 7.26 4.00 II experienced 3.9-4.5-5.0 1,790 4,177 2,38 7.25 4.13 III experienced 3.9-5.0-5.5 1,770 4,172 2.40 7.22 4.16 IV experienced 3.9-5.0-6.0 1,750 4,170 2.43 7.18 4.19

As the data in table 2 show, increasing the fiber level in broiler diets to 6% at the finish line, when using the proposed preparation, allowed us to obtain quite satisfactory results comparable to the control, where the fiber level did not increase above 4.8% at the finishing diet. Thus, the proposed drug can significantly change the structure of the diets for broiler chickens, increasing the input of meal from sunflower, which reduces the cost of feed.

Example 2. Scientific and economic experience on laying hens of cross-country Uk - Kuban 123 was carried out at the Novo-Myshastovskaya poultry farm, Krasnoarmeysky district. Krasnodar Territory. The diets of the control and experimental groups consist of feed of plant origin, the basis of which was wheat, barley, corn, sunflower meal, rice flour, mineral and vitamin supplements. In the experimental group, the proposed preparation was added at the rate of 2 kg per 1 ton of feed mixture. The results of the experiment are shown in table 3.

Table 3 The experience of feeding laying hens with the proposed drug Indicator Group control experienced Live weight at the beginning of the experiment, g 1802 1818 Live weight at the end of the experiment, g 1770 1760 The safety of the livestock,% 98 100 Egg production, pcs.,% 72,2 80.7 Feed costs per 1 goal / g 124.7 122.9 Feed costs in kg per 10 pcs. eggs 1.73 1,52 Eggs received (total) 1511 1694 Shell thickness 35.03 35.10 Egg weight (average), g 59.9 59.5

The data presented in the table indicate that the proposed probiotic preparation "Bacell" increases the safety of the bird, its egg production, reducing feed costs by 10 eggs and without compromising the quality of the eggs.

Example 3. The experience on calves was carried out in JSC them. Gorky, Leningrad region, Krasnodar Territory. The proposed drug was used on livestock calves. In the control and experimental groups were 15 goals at the age of 1-180 days. The probiotic supplement was introduced into the food of the experimental group under the age of 5 days, 4 g per day per head, and subsequently in the amount of 0.4% of the dry matter of the diet daily in accordance with the “Temporary instruction for the use of the probiotic preparation”.

Analyzing the experimental data, it can be noted that the proposed drug accelerated the formation of scar microflora, reduced the incidence of experimental animals and increased the eatability of roughage. In the experimental group, animal productivity (average daily gain) increased by 18-25%, safety - by 10%, feed consumption decreased by 15% compared with the control. Side effects and complications when using the proposed drug in the recommended doses have not been established.

Example 4. The experiment on fattening pigs was carried out in JSC “2nd Five-Year Plan” of the Leningrad District of Krasnodar Territory. The proposed drug "Bacell" was used against a background of diets with a high fiber content. The results of fattening pigs on diets of this type made it possible to obtain a gain in live weight of 550 g, which is 10 g worse than the control. However, the cost of 1 ton of such feed is approximately 350 rubles lower than the control. Thus, the use of the proposed drug for fattening pigs is economically justified.

Claims (1)

A probiotic composition for animals and birds containing the bacteria Rhuminococcus albus, Bacillus subtilis and the genus Lactobacillus, taken in equal amounts, characterized in that as Rhuminococcus albus contains a strain of Rhuminococcus albus Kr, and as Bacillus subtilis contains a strain of Bacillus subtilis VKPM-81 , and from bacteria of the genus Lactobacillus contains Lactobacillus acidophilus Scav. VKPM B-4625.